BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to HCT-15 cell line is 37
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | FACs followed by qRT-PCR and Western Blotting | NA | 0.6 | 1 | 24145190 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | FACs followed by qRT-PCR and SFA | NA | 0.6 | 1 | 28755485 |
| CD44 | 1681 | LTM | Colon Cancer | Adenocarcinoma | HCT-15 | Cisplatin | SFA and qPCR | NA | 0.6 | 1 | 34921482 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | FACs | NA | 0.6 | 1 | 26136074 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | Oxaliplatin | FACs | NA | 0.6 | 1 | 26136074 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 24145190 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 27997180 |
| POU5F1 | 9221 | LTM | Colon Cancer | Adenocarcinoma | HCT-15 | Cisplatin | SFA and qPCR | NA | 0.48 | 0.6448 | 34921482 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.6448 | 28946619 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.6448 | 21435460 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 24145190 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 27997180 |
| SOX2 | 11195 | LTM | Colon Cancer | Adenocarcinoma | HCT-15 | Cisplatin | SFA and qPCR | NA | 0.48 | 0.5695 | 34921482 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5695 | 28946619 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.5695 | 21435460 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | FACs followed by qRT-PCR and SFA | NA | 0.32 | 0.211 | 28755485 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.211 | 27997180 |
| ABCG2 | 74 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 27997180 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.684 | 27997180 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Adenocarcinoma | HCT-15 | Cisplatin | SFA and qPCR | NA | 0.28 | 0.684 | 34921482 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | RT-PCR followed by SFA | NA | 0.28 | 0.684 | 28946619 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.28 | 0.684 | 21435460 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | ALDEFLUOR assay | NA | 0.28 | 0.684 | 19923910 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 21720213 |
| BMI1 | 1066 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 27997180 |
| KLF4 | 6348 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0891 | 27997180 |
| KLF4 | 6348 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR | NA | 0.28 | 0.0891 | 24145190 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.7582 | 27997180 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by FACs | NA | 0.28 | 0.7582 | 21720213 |
| SCD | 10571 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0127 | 33430034 |
| CD24 | 1645 | LTM | Colon Cancer | Adenocarcinoma | HCT-15 | Cisplatin | SFA and qPCR | NA | 0.2 | 0.456 | 34921482 |
| DNAJB8 | 23699 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0021 | 24450541 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR | NA | 0.2 | 0.0753 | 24145190 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.2 | 0.0753 | 21435460 |
| LIN28A | 15986 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR | NA | 0.2 | 0.0138 | 24145190 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | qRT-PCR | NA | 0.2 | 0.5461 | 24145190 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | HCT-15 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.5461 | 28946619 |